Ensysce Biosciences Files 8-K: Material Agreement & Equity Sales

Ticker: ENSCW · Form: 8-K · Filed: Apr 24, 2025 · CIK: 1716947

Ensysce Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyEnsysce Biosciences, INC. (ENSCW)
Form Type8-K
Filed DateApr 24, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-filing

Related Tickers: ENSY

TL;DR

Ensysce Bio (ENSY) filed an 8-K detailing a new material agreement and equity sales. Watch for updates.

AI Summary

Ensysce Biosciences, Inc. announced on April 23, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Ensysce Biosciences?

The filing states that Ensysce Biosciences, Inc. entered into a material definitive agreement on April 23, 2025, but the specific details of this agreement are not provided in the summary information.

What type of equity securities were sold by Ensysce Biosciences?

The filing mentions "Unregistered Sales of Equity Securities" as an item of disclosure, but the specific type and amount of securities are not detailed in the provided text.

What are the "Other Events" reported in this 8-K filing?

The filing lists "Other Events" as a category of information, but the specific events are not elaborated upon in the provided summary.

When was Ensysce Biosciences, Inc. formerly known as Leisure Acquisition Corp.?

Ensysce Biosciences, Inc. was formerly known as Leisure Acquisition Corp. prior to a name change on September 13, 2017.

What is the principal executive office address for Ensysce Biosciences, Inc.?

The principal executive offices of Ensysce Biosciences, Inc. are located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2025 regarding Ensysce Biosciences, Inc. (ENSCW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing